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To the Editor We read a recent review by Jawień1 
with great interest. It is a significant voice in 
the field of atherosclerosis. Being excellent, this 
paper raises a few concerns for human studies 
in comparison with the animal model. However, 
a few opinions presented in the review, namely, 
that “humans lack Th1 and Th2 polarization that 
is observed in mice” and that “FoxP3 expression 
is a useful marker of Treg cells in mice, but not in 
humans”, need some commentary.
The first point to be discussed is the polariza-
tion of T-helper (Th) 1 and Th2 lymphocytes in 
humans. Different infectious agents evoke an ad-
equate adaptive immune response that clears 
an infection. The immune system adapts itself to 
the specific conditions of infection by producing 
different profiles of cytokines, which drive naïve 
CD4 T cells to differentiate into appropriate ef-
fector Th subset: Th1 or Th2. This step is critical 
for effective immune response because it deter-
mines its path – cellular or humoral. From these 
2 subsets of T cells, Th1 are the main contribu-
tors to atherosclerosis and their characteristic cy-
tokine, interferon-γ (IFN-γ), is observed in human 
plaques. The abundance of IFN-γ has not only dra-
matic consequences because of the activation of 
macrophages, but also causes decreased collagen 
fiber formation, higher expression of major his-
tocompatibility complex class II, enhanced pro-
tease and chemokine secretion, upregulation of 
adhesion molecules, and induction of proinflam-
matory cytokines. Interleukin 4, the cytokine of 
Th2 lineage, is in fact rarely observed in human 
plaques, which, in line with the available data, 
proves the crucial role of Th1 subset in the patho-
genesis of atherosclerosis, probably also in hu-
mans. The presence of Th1/Th2 polarized lym-
phocytes in humans has been confirmed in preg-
nancy and numerous clinical conditions, e.g., al-
lergic disorders.2‑4
Second issue that needs to be clarified is fork-
head box 3 (FoxP3) as a marker of human regula-
tory T (Treg) lymphocytes. The characterization of 
Treg cells by the expression of FoxP3 protein, ini-
tially in mice and subsequently in humans, was 
a critical step in the elucidation of their biology. 
Mutation of the FoxP3 gene in mice was originally 
connected with X-linked recessive inflammatory 
disease. Further studies in humans demonstrat-
ed that mutation in human FoxP3 gene is respon-
sible for X-linked immunodeficiency syndrome 
(also known as immune dysregulation, polyen-
docrinopathy, enteropathy, X-linked syndrome). 
FoxP3 belongs to the family of transcription fac-
tors and is the main controller during Treg-cell de-
velopment, and a hallmark of active Treg cells. Hu-
man Treg cells were first characterized by the pres-
ence of CD4 and CD25 molecules, the same as in 
the mice model. In fact, the FoxP3 gene was de-
scribed as a master gene controlling the devel-
opment of Treg cells in mice. Subsequently, it was 
shown that the human version of FoxP3 protein 
is also crucial for the function of human Treg cells. 
Furthermore, FoxP3 is exclusively expressed by 
CD25+CD4+ Treg cells, while other T cells, B  cells, 
and natural killer cells do not express it. Treg cells 
are commonly classified as “natural” and “induced”. 
A natural subset, which develops and emigrates 
from the thymus, is CD4+CD25+. Induced Treg cells 
are also characterized as CD4+CD25+, but they ac-
quire CD25 (α chain of the interleukin 2 receptor) 
outside the thymus. 
There have been several reports describing 
the role of Treg cells in several pathologies both 
in humans and in the murine model.5 It is crucial 
to be aware of the pivotal differences but also sim-
ilarities between animal models and humans.
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